Undisclosed B7-H3-targeted GADLEN / Shattuck - LARVOL DELTA

Antigen targeted butyrophilin heterodimer-based bispecific engagers induce Vγ9δ2+ T cell-mediated anti-tumor activity (SITC 2022) - "Methods Specificity of CD20- and B7H3-targeting GADLENs were evaluated using ELISA and cell-based assays by flow cytometry...Introduction of CD20-GADLEN into NSG-hIL15 mice engrafted with human PBMCs efficiently depleted human CD20+ B cells in the blood and spleen. Similarly, coadministration of GADLEN with Vγ9δ2 + T cells reduced tumor growth in tumor xenografts. Conclusions These results provide proof of concept for in vivo manipulation of γδ T cells using antigen targeted GADLENs for the treatment of hematologic and solid tumor malignancies."

IO biomarker • Oncology • Solid Tumor • BTN2A1 • BTN3A1 • CD20 • CD276 • NKG2D

Shattuck Labs Presents Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire) - "Shattuck Labs, Inc...announced preclinical data from the company’s novel GADLEN platform at the 2022 SITC Annual Meeting....Shattuck presented preclinical data highlighting the potential of GADLENs to direct Vγ9δ2+ T cells to kill tumor cells. The bispecific GADLENs, which contain heterodimeric BTN2A1 and BTN3A1 extracellular domains fused via inert Fc linkers to scFv domains, targeting CD20 or B7-H3 antigens, demonstrated cytotoxic ability in coculture with Vγ9δ2+ T cells. CD20-directed GADLENs enhanced the specific killing of lymphoma cells and healthy B cells that express the antigen, while B7H3-directed GADLEN increased the killing of B7-H3 expressing tumor cells."

Preclinical • Hematological Malignancies • Lymphoma • Oncology